CataX AI secures 40 million RMB for AI-assisted drug development
Shanghai-based startup CataX AI has raised 40 million RMB in seed funding from Qiming Venture Partners to advance its AI-driven clinical development platform.

Shanghai-based CataX AI has raised 40 million RMB in a seed funding round. Qiming Venture Partners, which incubated the startup, served as the sole investor for the round.
The company utilizes an operating model dubbed "Clinical-of-One," which integrates AI agents to assist human specialists in reviewing research, drafting regulatory documents, and processing complex data. The company plans to leverage this technology to license or co-develop drug candidates through preclinical and early clinical stages, aiming to achieve clinical proof of concept more efficiently.
Leadership includes CEO Wang Zilong, who holds a background in clinical medicine and AI research at Microsoft Research Asia, and co-founder Jiang Zhemin, who brings over 15 years of experience in clinical development. CataX AI intends to scale its operations by reusing data and methodologies across different development programs.